Press Releases

Gilead Sciences to Release Fourth Quarter and Year End 2004 Financial Results on Thursday, January 27, 2005; Conference Call and Webcast to Follow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 21, 2005--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its fourth quarter and year end 2004 financial results will be released on Thursday, January 27, 2005, at 4:00 p.m. Eastern Time. At 4:30 p.m. Eastern Time Gilead will webcast a conference call live on the company's internet site. The call will be led by John Martin, PhD, President and Chief Executive Officer, John Milligan, PhD, Executive Vice President and Chief Financial Officer, and Kevin Young, Executive Vice President, Commercial Operations. Gilead management will discuss the company's fourth quarter and year end 2004 results, provide an overview of the company, and an outlook and financial guidance for 2005.

To access the webcast via the internet, log on to Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 800-299-8538 (U.S.) or 617-786-2902 (international) and dial the participant passcode 86874997 to access the call. Telephone replay is available approximately two hours after the call through 6:30 p.m. Eastern Time, January 30, 2005. To access, please call 888-286-8010 (U.S.) or 617-801-6888 (international) and dial the participant passcode 40798211. The webcast will be archived on for one year.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has seven marketed products, and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit the company's web site at or call the Gilead Public Affairs Department at 800-GILEAD-5 (800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investor Relations)

SOURCE: Gilead Sciences, Inc.